DEXCOM INC — Director's Dealing 2023

Jan 31, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2023-01-30

Reporting Person: SAYER KEVIN R (Director, President CEO and Chairman of)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-30	Common Stock	S	47693	$106.0564	Disposed	378952	Direct
2023-01-30	Common Stock	S	9151	$106.6523	Disposed	369801	Direct

Footnotes

F1: On November 1, 2022, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2: This transaction was executed in multiple trades at prices ranging from $105.521 to $106.48. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3: Included in this number are 134,792 unvested restricted stock units, 65,004 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 35,852 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 33,936 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

F4: This transaction was executed in multiple trades at prices ranging from $106.50 to $106.91. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.